Overview
VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2023-06-01
2023-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine (1) whether vitamin D reduces incident total, non-vertebral fractures, and hip fractures and (2) whether this reduction is modified by vitamin D levelsPhase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Brigham and Women's HospitalCollaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Treatments:
Cholecalciferol
Ergocalciferols
Vitamin D
Vitamins
Criteria
All participants in VITAL (NCT 01169259) are eligible to participate in this ancillarystudy.